Wan; Honghe

Patent Applications and Registrations

Patent applications and USPTO patent grants for Wan; Honghe.The latest application filed is for "agonists of ror gammat".

Company Profile

1.9.15

Wan; Honghe - Pennington NJ
Wan; Honghe - Princeton NJ
Wan, Honghe - Kearny NJ

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
AGONISTS OF ROR GAMMAt App 20220306630 - Harikrishnan; Lalgudi S. ; et al.	2022-09-29
Macrocyclic Toll-like Receptor 7 (tlr7) Agonists App 20210053979 - PURANDARE; Ashok V. ; et al.	2021-02-25
Prodrugs of imidazotriazine compounds as CK2 inhibitors Grant 10,550,125 - Purandare , et al. Fe	2020-02-04
Prodrugs Of Imidazotriazine Compounds As Ck2 Inhibitors App 20180305364 - Purandare; Ashok Vinayak ; et al.	2018-10-25
Crystalline forms of N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-- 1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders Grant 9,593,116 - Purandare , et al. March 14, 2	2017-03-14
Imidazotriazinecarbonitriles useful as kinase inhibitors Grant 9,556,178 - Purandare , et al. January 31, 2	2017-01-31
Imidazotriazinecarbonitriles Useful As Kinase Inhibitors App 20160108050 - Purandare; Ashok Vinayak ; et al.	2016-04-21
Crystalline Forms Of N,n-dicyclopropyl-4-(1,5-dimethyl-1h-pyrazol-3-ylamino)-6-ethyl-1-methyl-- 1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboximide For The Treatment Of Myeloproliferative Disorders App 20160090385 - Purandare; Ashok Vinayak ; et al.	2016-03-31
Imidazotriazinecarbonitriles useful as kinase inhibitors Grant 9,273,057 - Purandare , et al. March 1, 2	2016-03-01
Imidazotriazinecarbonitriles Useful As Kinase Inhibitors App 20150210697 - Purandare; Ashok Vinayak ; et al.	2015-07-30
Imidazotriazinecarbonitriles Useful As Kinase Inhibitors App 20150065465 - Purandare; Ashok Vinayak ; et al.	2015-03-05
Imidazotriazinecarbonitriles useful as kinase inhibitors Grant 8,940,736 - Purandare , et al. January 27, 2	2015-01-27
JAK2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer Grant 8,673,933 - Purandare , et al. March 18, 2	2014-03-18
Imidazotriazinecarbonitriles Useful As Kinase Inhibitors App 20140018319 - Purandare; Ashok Vinayak ; et al.	2014-01-16
Jak2 Inhibitors And Their Use For The Treatment Of Myeloproliferative Diseases And Cancer App 20130225551 - Purandare; Ashok V. ; et al.	2013-08-29
JAK2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer Grant 8,202,881 - Purandare , et al. June 19, 2	2012-06-19
Jak2 Inhibitors And Their Use For The Treatment Of Myeloproliferative Diseases And Cancer App 20110059943 - Purandare; Ashok V. ; et al.	2011-03-10
Pyrrolotriazine kinase inhibitors Grant 7,531,539 - Fink , et al. May 12, 2	2009-05-12
Pyrrolotriazine Kinase Inhibitors App 20080045496 - Fink; Brian E. ; et al.	2008-02-21
Heterocyclic inhibitors of protein arginine methyl transferases App 20060235037 - Purandare; Ashok Vinayak ; et al.	2006-10-19
Compounds for the treatment of pain App 20030176314 - Forray, Carlos C. ; et al.	2003-09-18
Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors App 20030139431 - Kawakami, Joel K. ; et al.	2003-07-24

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.